Trial Profile
A Phase 1, Single Center, Dose-Escalation Study of SS1(dsFv)PE38 Administered Concurrently With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Epithelial Pleural Mesothelioma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Mesothelin SS dsFv PE38 (Primary) ; Cisplatin; Pemetrexed
- Indications Malignant-mesothelioma
- Focus Adverse reactions; Therapeutic Use
- 02 Aug 2018 Status changed to discontinued.
- 02 Aug 2018 Status changed to discontinued.
- 12 Nov 2015 Planned End Date changed from 1 Feb 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov record.